What is the brand name of the injectable drug submitted by Kang Pei Biotechnology for FDA review on June 3, 2026?

The brand name of the injectable drug is CBL-514, developed by Kang Pei Biotechnology.

What is the trial number of the Phase 3b long-term follow-up study for CBL-514 submitted on June 3, 2026?

The trial number is CBL-0303, submitted for the Phase 3b long-term follow-up study.

On what date did Kang Pei Biotechnology announce the FDA submission for CBL-514's Phase 3b trial?

Kang Pei Biotechnology announced the FDA submission on June 3, 2026.

What is the intended use of the CBL-514 injectable drug developed by Kang Pei Biotechnology?

CBL-514 is intended for abdominal fat reduction and was submitted for Phase 3b follow-up.

AI News NQ Analysis

【康霈】FDA Submission Completed for Phase 3b Long-Term Follow-up Clinical Trial of CBL-514 for Abdominal Fat Reduction

NQ Score 90/100

N1 Content Completeness 5

Key facts

【康霈】FDA Submission Completed for Phase 3b Long-Term Follow-up Clinical Trial of CBL-514 for Abdominal Fat Reduction
康霈生技 announced on June 3, 2026, the submission of its Phase 3b long-term follow-up clinical trial (CBL-0303) for the injectable drug CBL-514, intended for abdominal fat reduction, to the US FDA.
Source: TWSE
Date: Wed Jun 03 2026 09:00:00 GMT+0900 (Japan Standard Time)

Direct answer

康霈生技 announced on June 3, 2026, the submission of its Phase 3b long-term follow-up clinical trial (CBL-0303) for the injectable drug CBL-514, intended for abdominal fat reduction, to the US FDA.

Citation: 【康霈】FDA Submission Completed for Phase 3b Long-Term Follow-up Clinical Trial of CBL-514 for Abdominal Fat Reduction (Wed Jun 03 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
Source: TWSE
Date: Wed Jun 03 2026 09:00:00 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

康霈生技 announced on June 3, 2026, the submission of its Phase 3b long-term follow-up clinical trial (CBL-0303) for the injectable drug CBL-514, intended for abdominal fat reduction, to the US FDA.

AI Analysis

Frequently Asked Questions

Q: What is the brand name of the injectable drug submitted by Kang Pei Biotechnology for FDA review on June 3, 2026?: A: The brand name of the injectable drug is CBL-514, developed by Kang Pei Biotechnology.
Q: Which company submitted the Phase 3b long-term follow-up clinical trial CBL-0303 to the US FDA on June 3, 2026?: A: Kang Pei Biotechnology submitted the Phase 3b long-term follow-up clinical trial CBL-0303.
Q: What is the trial number of the Phase 3b long-term follow-up study for CBL-514 submitted on June 3, 2026?: A: The trial number is CBL-0303, submitted for the Phase 3b long-term follow-up study.
Q: On what date did Kang Pei Biotechnology announce the FDA submission for CBL-514's Phase 3b trial?: A: Kang Pei Biotechnology announced the FDA submission on June 3, 2026.
Q: What is the intended use of the CBL-514 injectable drug developed by Kang Pei Biotechnology?: A: CBL-514 is intended for abdominal fat reduction and was submitted for Phase 3b follow-up.